Navigation Links
Kiadis Pharma Reports Successful End of Phase II Meeting With FDA for Reviroc
Date:12/19/2007

FDA Offers Special Protocol Assessment for Reviroc

AMSTERDAM, December 19 /PRNewswire/ -- Kiadis Pharma announced today that it has successfully completed an End of Phase II meeting for Reviroc with the U.S. Food and Drug Administration (FDA). Reviroc is under development for elimination of cancer cells from an autologous graft in bone marrow transplantations for end-stage blood cancer patients. The FDA agreed that the data from the completed phase II clinical Reviroc trial is sufficient to support the start of a phase III study. The FDA offered Kiadis Pharma its Special Protocol Assessment (SPA) procedure allowing Kiadis Pharma to work directly with the FDA to optimize the clinical design of the trial.

The FDA meeting followed the successful completion of a multi centre phase II study for Reviroc showing an improved overall survival after autologous bone marrow transplantation in Non-Hodgkin's lymphoma patients. The phase III clinical trial design for Reviroc will focus on patients with Large B cell lymphoma. Kiadis Pharma anticipates filing of the IND, SPA request and Orphan Drug Designation application with the FDA within the next few weeks.

"We are very pleased with the outcome of the End of Phase II meeting with the FDA and with the possibility to access the FDA's Special Protocol Assessment program. Together with the strong support by our principal investigators we are well prepared to design a clear path towards marketing authorization for Reviroc," said Manja Bouman, CEO Kiadis Pharma.

About Reviroc

Reviroc is being developed as a treatment that eliminates blood cancer cells from autologous transplants for patients with end stage blood cancer. An autologous transplant uses the patient's own bone marrow to serve as a graft. Bone-marrow transplants are broadly recognized as a treatment option for patients suffering from blood cancers, such as leukemia and lymphoma. One of the limitations of autologous bone mar
'/>"/>

SOURCE Kiadis Pharma
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
2. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
3. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
4. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
5. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
6. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
7. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
8. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
9. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
10. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
11. Baxa Announces 2008 Dates for STAR Center Professional Pharmacy and Cleanroom Training
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... 2014 Research and Markets ... DNA Diagnostics Market (Product types, Application, Technology, End ... Company Profiles, Demand, Insights, Analysis, Research, Report, Opportunities, ... to their offering. This new ... end users and Geography) Global Size, Industry Analysis, ...
(Date:10/22/2014)... Involution Studios , a healthcare software ... infographic, Understanding Ebola . The goal of ... to follow informative tool for anyone wanting to know ... prevention. , "As the news has spread in all ... represents not only a healthcare crisis with global impact, ...
(Date:10/22/2014)... (PRWEB) October 22, 2014 According ... Market by Service Type (Consulting, Integration, Deployment & ... by Deployment Model (Public, Private, Others (Hybrid & ... MarketsandMarkets, defines and segments the Cloud Professional Services ... and forecasting of revenues. It also identifies the ...
(Date:10/22/2014)... DIEGO and HONG KONG ... innovative rare disease therapeutics enterprise, announced today that rare ... the company as vice president, research. Dr. McKew brings ... including key leadership positions at the National Institutes of ... its acquisition by Wyeth). Dr. McKew will lead aTyr,s efforts ...
Breaking Biology Technology:Global DNA Diagnostics Market (Product types, Application, Technology, End User and Geography) - Forecast to 2020 2Global DNA Diagnostics Market (Product types, Application, Technology, End User and Geography) - Forecast to 2020 3Involution Studios' Ebola Infographic Provides Key Disease Information and Statistics at a Glance 2Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 2Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 3Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 4Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 5aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3
... revenue growth ... Q3 2008 Highlights: - Product revenues ... - Direct (Non-OEM) Business revenues increased by 48% ... Calif., Oct. 27 Masimo Corporation,(Nasdaq: MASI ), the inventor of Pulse ...
... as Lead Epidemiologist, RALEIGH, N.C., Oct. 27 ... today the appointment of Dr.,Jerome Wilson as Senior ... Epidemiologist, Dr. Wilson is responsible for providing consulting,services ... PRA provides extensive Phase IV Post-Marketing services to,pharmaceutical ...
... JOSE, Calif., Oct. 27 HPSI (OTC Bulletin,Board: EROX) releases ... light of events that have shaken the investment community around ... to take this opportunity to update you as to ... Excluding technology advancements, an update of which will be ...
Cached Biology Technology:Masimo Reports Third Quarter 2008 Financial Results 2Masimo Reports Third Quarter 2008 Financial Results 3Masimo Reports Third Quarter 2008 Financial Results 4Masimo Reports Third Quarter 2008 Financial Results 5Masimo Reports Third Quarter 2008 Financial Results 6Masimo Reports Third Quarter 2008 Financial Results 7Masimo Reports Third Quarter 2008 Financial Results 8Masimo Reports Third Quarter 2008 Financial Results 9Masimo Reports Third Quarter 2008 Financial Results 10Masimo Reports Third Quarter 2008 Financial Results 11Masimo Reports Third Quarter 2008 Financial Results 12Masimo Reports Third Quarter 2008 Financial Results 13Jerome Wilson Joins PRA International's Late Phase Service Group 2Human Pheromone Sciences, Inc. - Shareholder Update 2Human Pheromone Sciences, Inc. - Shareholder Update 3
(Date:10/18/2014)... patients referred for evaluation of suspected genetic conditions, ... 25 percent, including detection of a number of ... disease, according to a study appearing in ... coincide with the American Society of Human Genetics ... or coding regions of thousands of genes simultaneously ...
(Date:10/17/2014)... news release is available in German . ... millions of sperms every day in order to reproduce? And ... are the topic of the latest issue of the research ... 2014). The evolutionary biologist Steven Ramm from Bielefeld University Bielefeld ... it is not unusual for a female to copulate with ...
(Date:10/16/2014)... constantly wages war on the human body. Battles ... stalemate. In pancreatic cancer, this stalemate—known as tumor ... aggressively malignant, a phenomena that is poorly understood. ... the laboratory of Salvatore Torquato, a Professor of ... conditions surrounding tumor dormancy and the switch to ...
Breaking Biology News(10 mins):Whole-exome sequencing shows potential as diagnostic tool 2Sperm wars 2Modeling tumor dormancy 2
... chemical processes in cells is dictated by the speed of ... a versatile method developed at the Institute of Physical Chemistry ... able to predict for the first time the diffusion coefficients ... is important not only for biologists and chemists, but also ...
... the first medication approved for the treatment of alcoholism ... part, by preventing the metabolism of an alcohol by-product, ... cause unpleasant symptoms, including nausea, vomiting, headache, and accelerated ... to avoid drinking. Beginning in the late ...
... alone were responsible for the demise of Australia,s iconic ... new study led by the University of Adelaide has ... study contradicts the widespread belief that disease must have ... thylacine was a unique marsupial carnivore found throughout most ...
Cached Biology News:Biologistics: How fast do chemical trains move in living cells? 2Biologistics: How fast do chemical trains move in living cells? 3Disulfiram: New support for an old addiction drug 2Disease not a factor in Tassie Tiger extinction 2
... Microarray Dot Blot Kits overcome this limitation ... over a wide range in low-density protein ... They are ideal for performing reverse-phase ... samples for the presence of low abundant ...
... easy-to-use kits for arraying proteins of ... common lab equipment. DiscoverLight Protein Array ... your protein, cell lysate or antibody ... kits include specially designed nitrocellulose membranes ...
Request Info...
... StabilZyme AP Conjugate Stabilizer is an ... bovine protein and other non-toxic stabilizing ... acid), pH 5.5 6.5. ... 0.02% methylisothiazolone and 0.02% bromonitrodioxane as ...
Biology Products: